Phase 2 pivotal registrational study of BCB-276
Latest Information Update: 21 May 2025
At a glance
- Drugs BCB 276 (Primary)
- Indications Diffuse intrinsic pontine glioma
- Focus Registrational; Therapeutic Use
Most Recent Events
- 15 May 2025 According to BrainChild Bio media release, BrainChild Bio advancing BCB-276 towards BLA submission with a single pivotal Phase 2 trial planned to commence in Q4 2025
- 14 Jan 2025 New trial record
- 07 Jan 2025 According to BrainChild Bio media release, company look forward to the initiation of the BCB-276 pivotal trial by the end of 2025.